share_log

中國中藥:中期報告 2024

TRAD CHI MED: Interim Report 2024

HKEX ·  Sep 26, 2024 04:34

Summary by Moomoo AI

中國中藥(TRAD CHI MED)發布了截至2024年6月30日的中期報告。報告顯示,公司總收入從上一年的93億元增長至約83.85億元,增長率為9.9%。然而,淨利潤從上年的8.81億元下降至7.54億元,下降了14.3%。營業利潤從上年的13.05億元增加至15.77億元,增長了20.8%。總資產從上年的49.31億元下降至34.8億元,下降了29.4%。公司的負債總額從20.34億元增加至24.18億元,增長了18.9%。此外,報告還提到了公司的ESG表現和未來的發展策略。中國中藥在報告期間的經營活動表現出穩定的增長,但淨利潤的下降可能會引起投資者的關注。
中國中藥(TRAD CHI MED)發布了截至2024年6月30日的中期報告。報告顯示,公司總收入從上一年的93億元增長至約83.85億元,增長率為9.9%。然而,淨利潤從上年的8.81億元下降至7.54億元,下降了14.3%。營業利潤從上年的13.05億元增加至15.77億元,增長了20.8%。總資產從上年的49.31億元下降至34.8億元,下降了29.4%。公司的負債總額從20.34億元增加至24.18億元,增長了18.9%。此外,報告還提到了公司的ESG表現和未來的發展策略。中國中藥在報告期間的經營活動表現出穩定的增長,但淨利潤的下降可能會引起投資者的關注。
Trad chi med (TRAD CHI MED) released its interim report for the period ending June 30, 2024. The report shows that the company's total revenue increased from the previous year's 9.3 billion yuan to approximately 8.385 billion yuan, a growth rate of 9.9%. However, net profit decreased from the previous year's 0.881 billion yuan to 0.754 billion yuan, a decrease of 14.3%. Operating profit increased from the previous year's 1.305 billion yuan to 1.577 billion yuan, a growth of 20.8%. Total assets decreased from the previous year's 4.931 billion yuan to 3.48 billion yuan, a decrease of 29.4%. The company's total liabilities increased from 2.034 billion yuan to 2.418 billion yuan, an 18.9% increase. In addition, the report also mentioned the company's esg performance and future development strategy. Trad chi med showed stable growth in operational activities during the reporting period, but the decrease in net profit may attract investors' attention.
Trad chi med (TRAD CHI MED) released its interim report for the period ending June 30, 2024. The report shows that the company's total revenue increased from the previous year's 9.3 billion yuan to approximately 8.385 billion yuan, a growth rate of 9.9%. However, net profit decreased from the previous year's 0.881 billion yuan to 0.754 billion yuan, a decrease of 14.3%. Operating profit increased from the previous year's 1.305 billion yuan to 1.577 billion yuan, a growth of 20.8%. Total assets decreased from the previous year's 4.931 billion yuan to 3.48 billion yuan, a decrease of 29.4%. The company's total liabilities increased from 2.034 billion yuan to 2.418 billion yuan, an 18.9% increase. In addition, the report also mentioned the company's esg performance and future development strategy. Trad chi med showed stable growth in operational activities during the reporting period, but the decrease in net profit may attract investors' attention.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more